Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$154.64 USD
+0.36 (0.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $155.00 +0.36 (0.23%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$154.64 USD
+0.36 (0.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $155.00 +0.36 (0.23%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Q3 Earnings Season Preview
by Sheraz Mian
All the big banks are on this week's reporting docket
Crash-Proof Stocks To Buy Now
by Brian Bolan
Crashes happen, but not all stocks are treated the same during the crash.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
Banks in Focus as Q2 Earnings Season Ramps Up
by Sheraz Mian
Banks had an overall decent time in Q2.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
The Republican- led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
The Republican-led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
The Republican-led House proposed budget -- which calls for a repeal of Obamacare in its entirety -- came as a bit of good news for the MedTech majors.
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss
by Zacks Equity Research
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
A Good Start to Q2 Earnings Season
by Sheraz Mian
The 2014 Q2 earnings season has gotten off to a relatively positive start.